Jingxun Wu

2.7k total citations · 2 hit papers
33 papers, 1.4k citations indexed

About

Jingxun Wu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Jingxun Wu has authored 33 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 7 papers in Surgery. Recurrent topics in Jingxun Wu's work include Lung Cancer Treatments and Mutations (13 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Peptidase Inhibition and Analysis (7 papers). Jingxun Wu is often cited by papers focused on Lung Cancer Treatments and Mutations (13 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Peptidase Inhibition and Analysis (7 papers). Jingxun Wu collaborates with scholars based in China, Australia and United States. Jingxun Wu's co-authors include Long Sun, Haojun Chen, Yizhen Pang, Bing Hao, Hua Wu, Qin Lin, Liang Zhao, Han‐Xiang An, Xuan Wu and Jing Wu and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and European Journal of Nuclear Medicine and Molecular Imaging.

In The Last Decade

Jingxun Wu

32 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer

2020 398 citations Haojun Chen, Yizhen Pang et al. European Journal of Nuclear Medicine and Molecular Imaging profile →
Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer

2021 246 citations Xinmin Yu, Jun Zhao et al. profile →

Peers

Countries citing papers authored by Jingxun Wu

Since Specialization

Citations

This map shows the geographic impact of Jingxun Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jingxun Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jingxun Wu more than expected).

Fields of papers citing papers by Jingxun Wu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jingxun Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jingxun Wu. The network helps show where Jingxun Wu may publish in the future.

Co-authorship network of co-authors of Jingxun Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Jingxun Wu. A scholar is included among the top collaborators of Jingxun Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jingxun Wu. Jingxun Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Novel insights from comprehensive analysis: The role of cuproptosis and peripheral immune infiltration in Alzheimer’s disease 2025 ·PLoS ONE ·(unknown), (unknown), (unknown), Jingxun Wu, Yidan Zhang, (unknown), Min Bi, Naian Xiao, (unknown), Bin Jiang	0
2	ALYREF recruits ELAVL1 to promote colorectal tumorigenesis via facilitating RNA m5C recognition and nuclear export 2024 ·npj Precision Oncology ·(unknown), Jingxun Wu, Bingqian Zhou, (unknown), Xicheng Wang, Feng Ye, Xiaoting Lin	11
3	Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non–Small Cell Lung Cancer: The Phase II TRUST-I Study 2024 ·Journal of Clinical Oncology ·Wěi Li, Anwen Xiong, Nong Yang, Huijie Fan, (unknown), (unknown), Yongsheng Wang, Xue Meng, Jingxun Wu, Ziping Wang, Yunpeng Liu, Xicheng Wang, (unknown), Kaihua Lu, (unknown), Yizhong Ren, Xianyu Zhang, Bing Yan, Christine M. Lovly, Caicun Zhou	16
4	SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer 2023 ·Journal for ImmunoTherapy of Cancer ·Jun Zhao, Xinmin Yu, Dingzhi Huang, Zhiyong Ma, Bo Gao, Jiuwei Cui, Qian Chu, Qing Zhou, Meili Sun, Daphne Day, Jingxun Wu, Hongming Pan, Lifeng Wang, Mark Voskoboynik, Zhehai Wang, Yunpeng Liu, Hui Li, Juan Zhang, (unknown), Yi‐Long Wu	15
5	Case Report: Dacomitinib is effective in lung adenocarcinoma with rare EGFR mutation L747P and brain metastases 2022 ·Frontiers in Oncology ·Yibin Li, (unknown), Bin Jiang, Chengkun Han, Feng Ye, Jingxun Wu	1
6	The prognostic impact of immune checkpoint inhibitors for the treatment of pulmonary sarcomatoid carcinoma: A multicenter retrospective study 2022 ·Neoplasma ·(unknown), Yue Hao, (unknown), Xingxiang Pu, Liping Wang, Zhansheng Jiang, Jingxun Wu, Qian Wang, (unknown), Wenxian Wang, Zhengbo Song	6
7	Transcription factor KLF15 inhibits the proliferation and migration of gastric cancer cells via regulating the TFAP2A-AS1/NISCH axis 2021 ·Biology Direct ·Xin Zhao, Linlin Chen, Jingxun Wu, (unknown), (unknown), Feng Ye	23
8	Combination cyclin-dependent kinase 4/6 inhibitors and endocrine therapy versus endocrine monotherapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: A systematic review and meta-analysis 2020 ·PLoS ONE ·Jiani Zheng, Jingxun Wu, Chunyue Wang, Shiwen Zhuang, Jianbo Chen, Feng Ye	18
9	Usefulness of [68Ga]Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [18F]FDG PET/CT findings 2020 ·European Journal of Nuclear Medicine and Molecular Imaging ·Haojun Chen, Liang Zhao, Dan Ruan, Yizhen Pang, Bing Hao, Yaqing Dai, Xiurong Wu, Wei Guo, Chunlei Fan, Jingxun Wu, Weipeng Huang, Qin Lin, Long Sun, Hua Wu	172
10	Estrogen receptor α is involved in the regulation of ITGA8 methylation in estrogen receptor-positive breast cancer 2020 ·Annals of Translational Medicine ·Jingxun Wu, Jianghong Cheng, Fu-Xing Zhang, Xianyang Luo, Zhiming Zhang, Shuai Chen	12
11	<p>Efficacy of Olanzapine-Triple Antiemetic Regimen in Patients with Gastrointestinal Tumor and High Risk of Chemotherapy-Induced Nausea and Vomiting Receiving Moderately Emetogenic Chemotherapy: A Retrospective Study</p> 2020 ·Cancer Management and Research ·Xuan Wu, Jingxun Wu, Gangling Tong, Boran Cheng, Minhua Chen, (unknown), (unknown), (unknown), Shubin Wang	5
12	Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer breakdown → 2020 ·European Journal of Nuclear Medicine and Molecular Imaging ·Haojun Chen, Yizhen Pang, Jingxun Wu, Liang Zhao, Bing Hao, Jing Wu, Jihong Wei, (unknown), Long Zhao, Zuoming Luo, (unknown), Chengrong Xie, Long Sun, Qin Lin, Hua Wu	398
13	Meningeal metastasis patients with EGFR G724S who develop resistance to osimertinib benefit from the addition of afatinib 2020 ·Translational Lung Cancer Research ·Yibin Li, (unknown), Jingxun Wu, Feng Ye	6
14	EGFR-TKI-based vs non-EGFR-TKI-based adjuvant therapy in resected non-small-cell lung cancer with EGFR mutations: a meta-analysis of randomized controlled trials 2018 ·OncoTargets and Therapy ·Jingxun Wu, (unknown), (unknown), (unknown), Haojun Chen, Long Sun, Hua Wu	6
15	S-1-based versus 5-FU-based chemotherapy as first-line treatment in advanced gastric cancer: a meta-analysis of randomized controlled trials 2014 ·Tumor Biology ·(unknown), Zhenkui Pan, Feng Ye, Han‐Xiang An, Jingxun Wu	17
16	Clinicopathological and prognostic significance of chemokine receptor CXCR4 overexpression in patients with esophageal cancer: a meta-analysis 2013 ·Tumor Biology ·Jingxun Wu, Xuan Wu, Wenhua Liang, Chunling Chen, Lingling Zheng, Han‐Xiang An	40
17	Open-label, single-arm phase II study of pemetrexed in the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma who have had prior platinum-based chemotherapy 2012 ·Cancer Chemotherapy and Pharmacology ·Yang Zhang, Liping Zhao, Pei-Yu Huang, Jingxun Wu, Feng‐Hua Wang, Yan Huang, Li Zhang	8
18	Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib 2012 ·OncoTargets and Therapy ·(unknown), Fei Xu, Jingxun Wu, Cong Xue, Yuanyuan Zhao, Wei Jiang, Liping Lin, Xuan Wu, Yachao Lu, Hua Bai, Jiasen Xu, Guanshan Zhu	45
19	National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China 2012 ·Lung Cancer ·Cong Xue, Zhihuang Hu, Wei Jiang, Yuanyuan Zhao, Fei Xu, Yan Huang, Hongyun Zhao, Jingxun Wu, Yang Zhang, Liping Zhao, Jing Zhang, Likun Chen, Li Zhang	91
20	[Analysis of the relationship between the response after the First-line chemotherapy and the survival in the advanced non-small cell lung cancer.]. 2008 ·PubMed ·Liping Lin, (unknown), (unknown), Hongyun Zhao, Yang Zhang, Jingxun Wu, Yuanyuan Zhao, (unknown), Li Zhang	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact